Compare Adecoagro SA (AGRO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Vertex Pharmaceuticals Incorporated — how do they compare? Adecoagro SA trades at $9.67 (market cap $1.36B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 98.7× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AGRO | VRTX | |
|---|---|---|
Market Cap | $1.36B | $134.25B |
Sector | Technology | Health |
52-Week High | $15.25 | $529.65 |
52-Week Low | $7.13 | $376.62 |
Enterprise Value | $3.39B | $128.37B |
Dividend Yield | 3.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
